AMSC And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) – AMSC (AMSC.OL), OKEANIS ECO TANKER (OET.OL), ELIS (ELIS.PA) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. AMSC (AMSC.OL)

1395% sales growth and 8.21% return on equity

AMSC ASA, through its subsidiaries, invests in maritime assets and companies in the United States. It operates one international subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was incorporated in 2005 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, AMSC has a trailing twelve months EPS of kr2.85.

PE Ratio

AMSC has a trailing twelve months price to earnings ratio of 10.07. Meaning, the purchaser of the share is investing kr10.07 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 102.25M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AMSC’s EBITDA is 465.79.

More news about AMSC.

2. OKEANIS ECO TANKER (OET.OL)

1384.1% sales growth and 28.08% return on equity

Okeanis Eco Tankers Corp., a shipping company, owns and operates tanker vessels worldwide. It operates a fleet of 14 tanker vessels comprising six modern Suezmax tankers and eight modern VLCC tankers focusing on the transportation of crude oil. The company was incorporated in 2018 and is based in Neo Faliro, Greece.

Earnings Per Share

As for profitability, OKEANIS ECO TANKER has a trailing twelve months EPS of kr40.06.

PE Ratio

OKEANIS ECO TANKER has a trailing twelve months price to earnings ratio of 8.56. Meaning, the purchaser of the share is investing kr8.56 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.08%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.5%, now sitting on 403.85M for the twelve trailing months.

More news about OKEANIS ECO TANKER.

3. ELIS (ELIS.PA)

77.2% sales growth and 7.22% return on equity

Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. The company was founded in 1883 and is headquartered in Saint-Cloud, France.

Earnings Per Share

As for profitability, ELIS has a trailing twelve months EPS of €1.06.

PE Ratio

ELIS has a trailing twelve months price to earnings ratio of 19.87. Meaning, the purchaser of the share is investing €19.87 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.22%.

Volume

Today’s last reported volume for ELIS is 399828 which is 39.83% above its average volume of 285924.

More news about ELIS.

4. SPBK1 NORD-NORGE (NONG.OL)

16.3% sales growth and 16.76% return on equity

SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market and Corporate Market segments. The company offers mortgage, car, boat, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers accounting services, real estate brokerage, and leasing/sale-leaseback financing, internet banking, and mobile services. SpareBank 1 Nord-Norge was founded in 1836 and is headquartered in Tromsø, Norway.

Earnings Per Share

As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr12.37.

PE Ratio

SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 8.62. Meaning, the purchaser of the share is investing kr8.62 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.76%.

Sales Growth

SPBK1 NORD-NORGE’s sales growth is 20% for the present quarter and 16.3% for the next.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 50.2% and 33.9%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 25.2%, now sitting on 5.55B for the twelve trailing months.

Volume

Today’s last reported volume for SPBK1 NORD-NORGE is 26517 which is 63.38% below its average volume of 72427.

More news about SPBK1 NORD-NORGE.

5. DNB BANK (DNB.OL)

12% sales growth and 15.02% return on equity

DNB Bank ASA provides financial services for individual and business customers in Norway and internationally. The company offers savings, current, and pension accounts; fixed rate and security deposits; home and cabin mortgages, car and consumer loans, business loans, and refinancing; car, house, home contents, travel, personal, and non-life insurance product; payment services; and online and mobile banking services, as well as cards. It also provides overdraft facilities; leasing services; factoring, supply chain, and receivable purchase financing services; bank guarantee, secure trading, documentary collection, and letter of credit services; investment banking services, such as mergers and acquisition, equity and debt capital market, shares and securities, mutual funds and trading, and bonds and commodities; and private financing, as well as equity trading, foreign exchange, interest rates, and risk advisory services. In addition, the company offers treasury management, working capital, trade finance, auto lease and equipment financing, and corporate finance services, as well as act as an estate agents. DNB Bank ASA was founded in 1822 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNB BANK has a trailing twelve months EPS of kr25.77.

PE Ratio

DNB BANK has a trailing twelve months price to earnings ratio of 8.44. Meaning, the purchaser of the share is investing kr8.44 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.02%.

Moving Average

DNB BANK’s value is higher than its 50-day moving average of kr202.30 and way above its 200-day moving average of kr193.35.

Volume

Today’s last reported volume for DNB BANK is 2633740 which is 99.68% above its average volume of 1318930.

Yearly Top and Bottom Value

DNB BANK’s stock is valued at kr217.60 at 12:20 EST, higher than its 52-week high of kr212.80.

More news about DNB BANK.

6. PROTECTOR FORSIKRG (PROT.OL)

8.1% sales growth and 31.31% return on equity

Protector Forsikring ASA, operates as a non-life insurance company, provides various insurance products to the commercial and public sectors, and the grouped insurance schemes markets in Norway, Denmark, Sweden, the United Kingdom, and Finland. It operates in Commercial Lines of Business and Public Lines of Business segments. The company offers personal insurance, including personal and collective accident, critical illness, group life, health, and travel insurance; motor insurance; property insurance; and liability insurance. It sells its products through insurance brokers and agents. Protector Forsikring ASA was founded in 2003 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PROTECTOR FORSIKRG has a trailing twelve months EPS of kr16.54.

PE Ratio

PROTECTOR FORSIKRG has a trailing twelve months price to earnings ratio of 14.03. Meaning, the purchaser of the share is investing kr14.03 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.31%.

Volume

Today’s last reported volume for PROTECTOR FORSIKRG is 25731 which is 69.58% below its average volume of 84591.

Yearly Top and Bottom Value

PROTECTOR FORSIKRG’s stock is valued at kr232.00 at 12:20 EST, way under its 52-week high of kr265.00 and way higher than its 52-week low of kr160.00.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 3564.3% and a drop 48.2% for the next.

More news about PROTECTOR FORSIKRG.

7. SANOFI (SAN.PA)

7.4% sales growth and 5.82% return on equity

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, SANOFI has a trailing twelve months EPS of €4.3.

PE Ratio

SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.

More news about SANOFI.

Leave a Reply

Your email address will not be published. Required fields are marked *